https://pubmed.ncbi.nlm.nih.gov/32781574/
Adrenocortical Carcinoma (ACC) is a rare but aggressive malignancy with poor prognosis and limited response to available systemic therapies. Although complete...
adrenocortical cancerkeymicrorna
https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-216106&utm_campaign=recommended-articles-pi
Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
adrenal cortex canceradrenocortical carcinomapembrolizumabmercklikelihood